相关实验视频

Updated: Feb 28, 2026

Renal Subcapsular Transplantation of 2'-Deoxyguanosine-Treated Murine Embryonic Thymus in Nude Mice

Renal Subcapsular Transplantation of 2'-Deoxyguanosine-Treated Murine Embryonic Thymus in Nude Mice

Published on: July 19, 2019

在De Novo脏移植接受者的Envarsus对Advagraf:一个比较的药理动力学研究

Patricio Más-Serrano^1,2,3, Antonio Franco^3,4, Marcos Díaz^1,3

¹Pharmacy Department, University General Hospital Dr. Balmis of Alicante, Calle Pintor Baeza 10, 03010 Alicante, Spain.

Life (Basel, Switzerland)

|February 27, 2026

概括

在脏移植患者中,Envarsus的早期暴露率高于Advagraf,长期需要更低的剂量. 建议进行仔细的早期监测,因为Envarsus的初始过度暴露风险较高.

科学领域:

腎臟病學 (nephrology) 是一種醫學專業.
药理学药理学是指药理学的学科.
移植免疫学移植免疫学

背景情况:

有限的现实世界的数据存在于每天一次的tacrolimus配方在移植中的药理动力学.
这项研究比较了Envarsus和Advagraf在移植后早期期间的塔克罗利斯暴露和剂量.

研究的目的:

为了比较tacrolimus的药理动力学,剂量和Envarsus和Advagraf之间的早期结局,在新的脏移植接受者中.
为了评估这两种每天服用一次的塔克罗利斯配方的实际有效性和安全性.

主要方法:

在成年 de novo 脏移植接受者中进行前性,观察性,单中心研究.
塔克罗利莫斯 (Envarsus或Advagraf) 开始于0.15毫克/公斤/天,与普得尼松和西罗利莫斯.
谷口度 (C0),每日剂量和C0/D在48小时和最长3个月后进行评估;剂量调整以治疗药物监测为指导.

主要成果:

与Advagraf相比,Envarsus在48小时内显示出更高的早期C0和C0/D (p < 0.001).
从第1周到第3个月,Envarsus需要较低的每日剂量 (p=0.001-0.021) 并保持较高的C0/D (p=0.001-0.012),而低谷度相似.
早期的低于治疗水平的低谷在Envarsus中较少 (6.7%vs 40.5%),但高于治疗水平的低谷更频繁 (57.8%vs 18.9%).

结论:

Envarsus提供了比Advagraf更高的早期和持续的剂量正常化塔克罗利斯暴露,允许更低的维护剂量.
短期有效性和安全性相似,但Envarsus在初始剂量时显示出早期过度暴露的风险增加.
建议在接受脏移植的新人中对Envarsus进行仔细的早期监测和潜在的剂量减少.

关键词:

这是一个advagraf.生物可用性生物可用性氨尿抗剂氨尿抗剂这就是Envarsussus的原因.免疫抑制是一种免疫抑制.药物动力学药物动力学

更多相关视频

Direct Drug Delivery to Kidney via the Renal Artery

Direct Drug Delivery to Kidney via the Renal Artery

Published on: April 17, 2021

Non-invasive Imaging of Acute Allograft Rejection after Rat Renal Transplantation Using 18F-FDG PET

Non-invasive Imaging of Acute Allograft Rejection after Rat Renal Transplantation Using 18F-FDG PET

Published on: April 28, 2013

相关概念视频

Renal Drug Clearance: Comparison Between Renal Excretion Methods

Renal Drug Clearance: Comparison Between Renal Excretion Methods

Renal clearance is a critical parameter encompassing kidney filtration, secretion, and reabsorption processes. It is calculated using a specific equation to determine the rate at which the kidneys clear a drug.
Renal clearance is often associated with the renal glomerular filtration rate (GFR), which represents the rate at which plasma is filtered through the glomeruli in the kidney. When drug reabsorption is minimal and there is no active secretion, renal clearance is closely related to the...

Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate

Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate

The glomerular filtration rate (GFR) is a critical indicator of kidney health, reflecting how well the kidneys filter blood. Changes in GFR can signal potential kidney impairment, necessitating accurate measurement methods to monitor kidney function effectively.Various molecules can serve as markers for GFR measurement, with the ideal marker meeting several specific criteria. It must freely filter at the glomerulus, avoid reabsorption or secretion by the renal tubules, remain unmetabolized, not...

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...

Drug Dosing in Renal Diseases: Measurement of Serum Creatinine Concentration and Clearance

Drug Dosing in Renal Diseases: Measurement of Serum Creatinine Concentration and Clearance

In healthy individuals, serum creatinine levels remain stable due to a balance between its constant production—primarily from muscle metabolism—and renal excretion. Creatinine is freely filtered by the glomeruli, making it a valuable marker for estimating renal function. When the glomerular filtration rate (GFR) decreases, the kidneys can only eliminate less creatinine, causing serum levels to rise.Serum creatinine concentration is widely used to estimate creatinine clearance...

Renal Drug Clearance: Overview

Renal Drug Clearance: Overview

Renal clearance is a crucial parameter in pharmacokinetics that quantifies the rate at which the kidneys excrete a drug. It represents a constant fraction of the central volume of distribution containing the drug that the kidney eliminates per unit of time.
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...